Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Children 5-17 years of age.~2. Diagnosis of active Crohn's Disease.4. Patients with a PCDAI≥10 ≤40 (mild to moderate disease).~3. Have involvement of the colon and/or terminal ileum.~4. Disease defined as L1, L2, L3 or any of the above and may have gastric, duodenal or esophageal disease (L4a) according to the Paris classification for site of disease.~5. The CRP ≥ 0.6 mg/dL.~6. Duration of disease since diagnosis \< 3 years.~7. Negative stool culture, Clostridium Difficile Toxin from current flare.~Exclusion Criteria:~1. Duration of disease since diagnosis \> 3 years.~2. Positive stool culture or O\&P last 30 days.~3. Presence of clostridium difficile toxin in stool.~4. Azithromycin or Metronidazole allergy or known intolerance.~5. Diagnosis of IBD -U.~6. Presence of macroscopic disease involving the proximal ileum or jejunum (L4b).~7. Continuous macroscopic disease of the colon appearing as typical ulcerative colitis and Crohns diagnosed only by focality or granuloma on biopsies.~8. Presence of extraintestinal manifestations (such as arthritis, uveitis, or sclerosing cholangitis).Apthous lesions of mouth can be included.~9. Presence of fibrostenotic disease (strictures with prestenotic dilatation).~10. Presence of penetrating disease (fistulas or abscess).~11. Presence of current perianal disease defined as fistula or abscess.~12. Patients receiving concurrent corticosteroids or biologics.~13. Patients who have received steroids in the past 14 days.~14. Immune deficiency (CGD, GSD1, IL10R etc).~15. Known allergy or intolerance to any of the study medications.~16. Concurrent diseases such as hepatitis, ALT \>2 times UNL, renal failure.~17. Pregnancy.~18. Patients with known heart disease.~19. Prolonged QTc by E.C.G at baseline.~20. Patient after surgical resection.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin + Metronidazole (Type: EXPERIMENTAL): Oral Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the last 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
- Metronidazole (Type: ACTIVE_COMPARATOR): Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).